TY - JOUR T1 - Complete response to anti-IL5 biologics in a real-life setting JF - ERJ Open Research JO - erjor DO - 10.1183/23120541.00238-2022 SP - 00238-2022 AU - Marianne Baastrup Soendergaard AU - Susanne Hansen AU - Anne-Sofie Bjerrum AU - Ole Hilberg AU - Sofie Lock-Johansson AU - Kjell Erik Julius Haakansson AU - Truls Sylvan Ingebrigtsen AU - Claus Rikard Johnsen AU - Linda Makowska Rasmussen AU - Anna von Bülow AU - Karin Dahl Assing AU - Johannes Martin Schmid AU - Charlotte Suppli Ulrik AU - Celeste Porsbjerg Y1 - 2022/01/01 UR - http://openres.ersjournals.com/content/early/2022/06/16/23120541.00238-2022.abstract N2 - Background Phase III regulatory trials show that anti-IL 5 biologics efficiently reduce exacerbations and use of maintenance oral corticosteroids (mOCS) in patients with severe eosinophilic asthma. However, patients eligible for these trials differ significantly compared to real life severe asthma populations. Therefore, our aim was to explore efficacy in a real-life setting. The Danish Severe Asthma Register (DSAR) is a complete, nationwide register that comprises all Danish patients on biological therapy for severe asthma.Methods This prospective study identified patients in DSAR who were complete responders to anti IL5 biologics after one year of treatment. A complete response was defined as resolution of the parameter setting the indication, i.e. recurrent exacerbations and/or use of mOCS.Results A total of 289/502 (58%) were complete responders to anti-IL5 biologics after 12 months. Complete responders had greater improvements in FEV1 and Asthma Control Questionnaire (ACQ) compared to non-complete responders (Δ 210 mL versus Δ 30 mL, p<0.0001) and (Δ-1.04 versus Δ-0.68, p=0.016), respectively. A complete response was predicted by age at onset, less severe disease at baseline (i.e. no mOCS and lower ACQ score) and higher blood eosinophils.Conclusion More than half of Danish patients treated with anti-IL5 biologics for severe asthma achieve a complete response to treatment thereby becoming free from asthma exacerbations and need for mOCS. Complete responders also achieved superior effects on lung function and symptoms compared to non-complete responders.FootnotesThis manuscript has recently been accepted for publication in the ERJ Open Research. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJOR online. Please open or download the PDF to view this article.Conflict of interest: Kjell Erik Julius Håkansson has received unrestricted research grant, paid to institution from AstraZeneca and SanofiGenzyme, outside the submitted work. Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from AstraZeneca, TEVA, GSK and SanofiGenzyme, outside the submitted work.Conflict of interest: Marianne Baastrup Soendergaard has received lecture fees from GSK, outside the submitted work.Conflict of interest: Susanne HansenConflict of interest: Anne Sofie Bjerrum has received lecture fees from Astra Zeneca and GSK, outside the submitted work.Conflict of interest: Ole HilbergConflict of interest: Sofie Lock-JohanssonConflict of interest: Kjell Erik Julius HaakanssonConflict of interest: Truls Sylvan IngebrigtsenConflict of interest: Claus Rikard JohnsenConflict of interest: Linda Makowska Rasmussen has received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from AstraZeneca, GlaxoSmithKline, Teva and ALK, outside the submitted work. Support for attending meetings and/or travel received from AstraZeneca and Chiesi, outside the submitted work. Participation on a Data Safety Monitoring Board or Advisory Board for AstraZeneca, GlaxoSmithKline, Teva and Sanofi, outside the submitted work.Conflict of interest: Anna von Bülow has done consultancy work for Novartis DK, outside the submitted work. Lectures and speakers fees received from Astra Zenica, Novartis and GSK, outside the submitted work. Attended Advisory Board for Astra Zenica and Novartis, outside the submitted work.Conflict of interest: Karin Dahl AssingConflict of interest: Johannes Martin SchmidConflict of interest: Charlotte Suppli Ulrik received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from AZ, GSK, TEVA, Sanofi, Orion Pharma, Novartis, and Chiesi, outside the submitted work.Conflict of interest: Celeste Porsbjerg has received grants or contracts from AZ, GSK, Novartis, TEVA, Sanofi, Chiesi and ALK, outside the submitted work. Consulting fees from AZ, GSK, Novartis, TEVA, Sanofi, Chiesi and ALK, outside the submitted work. Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events, received from AZ, GSK, Novartis, TEVA, Sanofi, Chiesi and ALK, outside the submitted work. Participation on a Data Safety Monitoring Board or Advisory Board for AZ, Novartis, TEVA, Sanofi and ALK, outside the submitted work. ER -